AEON Biopharma, Inc. Stock: price and insider trades · United States

AEON Biopharma, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 11 filings came from 11 insiders.

Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €210k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 major shareholder among the declarants. One trade stands out by size: a purchase of €210k from Lynch Timothy P, disclosed on 21 August 2026, or 1.8% of market capitalisation.

For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 11 filings here. Looking back to 2023, when coverage begins, insiders filed 3 purchases and no sales.

The clock since the last published purchase (21 August 2026) now reads 58 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 5 days. Section 16 rules allow two business days to file each Form 4.

In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.